Carbapenem-Based Antibiotics Market Report 2025

The carbapenem-based antibiotics market size has grown steadily in recent years. It will grow from $4.6 billion in 2024 to $4.82 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to epidemics and pandemics, rise in chronic diseases, healthcare infrastructure growth, rapid urbanization, natural disasters and health emergencies.

The carbapenem-based antibiotics market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increased incidence of hospital-acquired infections, emergence of multi-drug resistant strains, growing aging population, rise in surgical procedures, proliferation of infectious diseases, changing demographics. Major trends in the forecast period include supply chain resilience and security, alternative treatment development, shift towards outpatient settings, growing awareness on antimicrobial stewardship, precision medicine approaches.

The rising incidence of bacterial infections is anticipated to drive the growth of the carbapenem-based antibiotics market in the future. Bacterial infections are caused by bacteria, which are microscopic organisms that can invade the body, leading to various diseases and symptoms. Carbapenem-based antibiotics are effective in treating severe or multidrug-resistant bacterial infections, including those caused by both gram-positive and gram-negative bacteria. For instance, in July 2024, a report published by the Centers for Disease Control and Prevention (CDC), a US government agency, noted that in 2023, 78% of all bacterial infections were diagnosed using culture-independent diagnostic tests (CIDTs) in the historic catchment area, with 46% diagnosed exclusively through CIDTs. Thus, the rising incidence of bacterial infections is propelling the growth of the carbapenem-based antibiotics market.

The increasing number of surgical procedures is also expected to contribute to the growth of the carbapenem-based antibiotics market in the future. Surgical procedures involve medical interventions performed by qualified surgeons to treat, repair, remove, or replace body parts affected by disease or injury. Carbapenems provide a broad spectrum of activity, effectively targeting infections in the abdominal cavity, combating infections, and reducing the necessity for combination therapy, thereby simplifying treatment regimens for surgical patients. For example, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based organization, reported that aesthetic procedures reached nearly 35 million in 2023, with the total number of surgical and non-surgical procedures increasing by 3.4% to 34.9 million. Therefore, the rising number of surgical procedures is driving the growth of the carbapenem-based antibiotics market.

Product innovations are a significant trend gaining traction in the carbapenem-based antibiotics market. Major companies in this sector are developing new products to maintain their competitive edge. For example, in August 2024, the National Health Service (NHS), a UK government department, introduced a groundbreaking subscription model for antibiotics in partnership with the pharmaceutical industry to address antimicrobial resistance (AMR). Announced on August 12, 2024, this innovative scheme allows pharmaceutical companies to receive fixed annual payments - up to £20 million per drug - regardless of the quantity prescribed, effectively eliminating incentives for overprescribing. Valued at approximately £1.9 billion over 16 years, the initiative aims to promote the development of new antibiotics by ensuring financial sustainability for drug manufacturers. Following a successful pilot phase, this initiative is part of the UK’s broader strategy to combat AMR, which poses a severe global health risk that could lead to millions of deaths by 2050 if not tackled. The NHS will prioritize products targeting critical pathogens identified by the World Health Organization, reinforcing its dedication to responsible antibiotic stewardship while encouraging innovation in antibiotic development.

Leading companies in the carbapenem-based antibiotics market are concentrating on investments to drive revenue growth. For instance, in September 2024, Hikma Pharmaceuticals, a US-based pharmaceutical company, launched Clindamycin Injection in 5% Dextrose in the United States, providing a new treatment option for severe bacterial infections caused by susceptible gram-positive bacteria. Available in ready-to-use 50 mL containers with dosages of 600 mg and 900 mg, this injectable antibiotic is especially advantageous for patients with penicillin allergies. The introduction of this product expands treatment options for healthcare providers managing complex infections, such as respiratory and skin infections, while reinforcing Hikma's commitment to tackling antibiotic resistance and enhancing patient care through accessible medication solutions.

In September 2022, GSK PLC, a pharmaceutical and biotechnology company based in the UK, and Spero Therapeutics, Inc. entered into an exclusive license agreement. The agreement involved an upfront payment of $66 million, with the potential for future milestone payments and tiered royalties. This exclusive license granted GSK the commercialization rights for tebipenem HBr in all regions except for Japan and certain other Asian countries. Spero Therapeutics, a US-based clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments and medicines for bacterial infections, including multi-drug resistant and rare diseases, particularly in the realm of carbapenem oral antibiotics.

Major companies operating in the carbapenem-based antibiotics market include Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation.

North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the carbapenem-based antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Carbapenem-based antibiotics represent a class of broad-spectrum antibacterial drugs known for their high efficacy against various bacterial infections. These antibiotics are particularly effective against both gram-positive and gram-negative bacteria, including strains that may be resistant to other types of antibiotics.

The primary types of carbapenem-based antibiotics include meropenem, imipenem, doripenem, tebipenem, and others. Meropenem, for instance, is a broad-spectrum antibiotic that works by inhibiting bacterial cell wall synthesis, making it effective against a wide range of bacterial infections. It is employed in the treatment of serious bacterial infections such as pneumonia, meningitis, intra-abdominal infections, urinary tract infections, and skin and soft tissue infections. Carbapenem-based antibiotics find application in treating various conditions, including intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin and skin structure infections, acute pelvic infections, prophylaxis of surgical site infection, respiratory tract infections, and gynecologic infections. These antibiotics are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The carbapenem-based antibiotics market research report is one of a series of new reports that provides carbapenem-based antibiotics market statistics, including the carbapenem-based antibiotics industry's global market size, regional shares, competitors with a carbapenem-based antibiotics market share, detailed carbapenem-based antibiotics market segments, market trends, and opportunities, and any further data you may need to thrive in the carbapenem-based antibiotics industry. This carbapenem-based antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carbapenem-based antibiotics market consists of sales of imipenem-cilastatin, meropenem, ertapenem, doripenem, biapenem, panipenem, tebipenem, razupenem, tomopenem, and faropenem. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.